AYTU - Aytu BioScience Inc logo

Aytu BioScience Inc

AYTU

Aytu BioPharma develops and commercializes prescription products for treating attention deficit hyperactivity disorder (ADHD) and allergy conditions in children, including extended-release tablets and fluoride-based multivitamins for pediatric patients.

โš•๏ธ Healthcare NASDAQ Listed 2017 $ USD
$1,000 invested 10 years ago โ†’$0today

Score Overview

1 Year
Score
Net Growth-80.23%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-5.64%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score5.3
Net Growth58.07%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-4.56%
Rev Trend60%
Revenue Consistencyโ€”
All Time
Score
Net Growth-8.60%
Net Trend56%
Net Income Consistency
Rev Growth19x
Rev Trend78%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Aytu BioScience Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. AYTU does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 1.98โ€”
1 Year2025-10-22
$ 2.27-12.78%
5 Years2021-10-22
$ 49.20-95.98%
10 Years2016-10-21
$ 176K-100.00%
All Time2017-02-01
$ 80K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 62M-$ 24M$ 30M
2025$ 66M-$ 13M$ 30M
2024$ 65M-$ 15M$ 20M
2023$ 107M-$ 17M$ 22M
2022$ 96M-$ 108M$ 19M
2021$ 65M-$ 58M$ 49M
2020$ 27M-$ 13M$ 48M
2019$ 7M-$ 47M$ 11M
2018$ 3M-$ 10M$ 7M
IPO2017$ 3M-$ 22M$ 802.33K
AYTU - Aytu BioScience Inc logo

Aytu BioScience Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 27M to $ 66M and net income went from -$ 13M to -$ 13M. Revenue increased in 3 of those 5 years; net income in 3.

Across Aytu BioScience Inc's full reported history, from 2017 to 2025, revenue grew from $ 3M to $ 66M and net income went from -$ 22M to -$ 13M. Revenue increased in 78% of the years measured; net income in 56%.

Aytu BioScience Inc currently holds a 5-year HDB Score of 5.3 out of 10. How the HDB Score is calculated.

Membership

Explore AYTU with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies